Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant.

Trial Profile

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Bendamustine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 29 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 25 Apr 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top